NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc.
- Market cap
- $124.12M
Your view on NRXP
Overview
What the company does, where it operates, and who runs it.
About NRx Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jonathan C. Javitt
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jonathan C. Javitt
- Headquarters
- US
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.
Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.
The company was founded in 2015 and is based in Wilmington, Delaware.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for NRx Pharmaceuticals, Inc.. Starting points for NRx Pharmaceuticals, Inc.: EPS -$0.46, beta 2.07 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for NRx Pharmaceuticals, Inc.. Trailing twelve-month EPS for NRx Pharmaceuticals, Inc. stands at -$0.46. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for NRx Pharmaceuticals, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| VTVTvTv Therapeutics Inc. | Healthcare | NASDAQ | $64.2M | ||
| VXL.VVaxil Bio Ltd. | Healthcare | TSXV | $410,937 | ||
| VXRTVaxart, Inc. | Healthcare | OTC | $129.3M | ||
| VYGRVoyager Therapeutics, Inc. | Healthcare | NASDAQ | $103.9M | ||
| WHWKWhitehawk Therapeutics Inc | Healthcare | NASDAQ | $184.7M | ||
| WINTWindtree Therapeutics, Inc. | Healthcare | NASDAQ | $1.8M | ||
| WSNAFWesana Health Holdings Inc. | Healthcare | OTC | $341,000 | ||
| WVEWave Life Sciences Ltd. | Healthcare | NASDAQ | $546.3M | ||
| WXIBFWuXi Biologics (Cayman) Inc. | Healthcare | OTC | $21.3B | ||
| WXXWYWuXi Biologics (Cayman) Inc. | Healthcare | OTC | $21.7B | ||
| XAGELongevity Health Holdings Inc. | Healthcare | OTC | $415,447 | ||
| XBIOXenetic Biosciences, Inc. | Healthcare | NASDAQ | $3.6M | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold NRx Pharmaceuticals, Inc., and how their positions are changing. At a $124.1M market value, institutional positions materially move NRx Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by NRx Pharmaceuticals, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for NRx Pharmaceuticals, Inc.. Coverage tracks NRx Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of NRx Pharmaceuticals, Inc.